S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
All the trading advice you’ve ever received boils down to this (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
All the trading advice you’ve ever received boils down to this (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
All the trading advice you’ve ever received boils down to this (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
All the trading advice you’ve ever received boils down to this (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
All the trading advice you’ve ever received boils down to this (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
All the trading advice you’ve ever received boils down to this (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
All the trading advice you’ve ever received boils down to this (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
All the trading advice you’ve ever received boils down to this (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way

Enfusion (ENFN) Stock Price, News & Analysis

$9.75
+0.09 (+0.93%)
(As of 12/8/2023 ET)
Compare
Today's Range
$9.52
$9.88
50-Day Range
$7.87
$10.23
52-Week Range
$7.37
$12.31
Volume
200,375 shs
Average Volume
278,801 shs
Market Capitalization
$1.24 billion
P/E Ratio
121.89
Dividend Yield
N/A
Price Target
$10.17

Enfusion MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
4.3% Upside
$10.17 Price Target
Short Interest
Healthy
4.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.66mentions of Enfusion in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$11.51 M Sold Last Quarter
Proj. Earnings Growth
100.00%
From $0.09 to $0.18 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Computer And Technology Sector

401st out of 583 stocks

Prepackaged Software Industry

128th out of 193 stocks


ENFN stock logo

About Enfusion Stock (NYSE:ENFN)

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. The company was founded in 1997 and is headquartered in Chicago, Illinois.

ENFN Stock Price History

ENFN Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Enfusion Names Neal Pawar COO - Quick Facts
Enfusion Announces Appointment of Chief Operating Officer
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Enfusion Inc Class A ENFN
Enfusion: Still Bullish Considering Q3 EBITDA Beat
Enfusion Adds 9% After Q3 Revenue Beats Estimates
Enfusion Announces Third Quarter 2023 Results
Is It Time To Consider Buying Enfusion, Inc. (NYSE:ENFN)?
Enfusion Announces Date of Third Quarter 2023 Results
Is Enfusion, Inc. (NYSE:ENFN) Trading At A 30% Discount?
Enfusion (NYSE: ENFN)
Enfusion Inc.
See More Headlines
Receive ENFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/05/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Fax
N/A
Employees
1,006
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.17
High Stock Price Target
$12.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+4.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-7,650,000.00
Pretax Margin
6.23%

Debt

Sales & Book Value

Annual Sales
$150.35 million
Book Value
$0.91 per share

Miscellaneous

Free Float
77,532,000
Market Cap
$1.24 billion
Optionable
Not Optionable
Beta
1.02
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Oleg Movchan (Age 48)
    CEO & Director
    Comp: $876.34k
  • Mr. Bradley Herring (Age 52)
    Chief Financial Officer
    Comp: $267.05k
  • Ms. Bronwen Bastone (Age 50)
    Chief People Officer
    Comp: $566.25k
  • Mr. Stephen Malherbe
    Managing Partner
  • Mr. Neal Pawar
    Chief Operating Officer
  • Mr. Daniel Groman (Age 34)
    Chief Technology Officer
  • Mr. Ignatius Tochukwu Njoku
    Head of Investor Relations
  • Matt Campobasso
    General Counsel
  • Caroline Ma
    Head of Corporate Development
  • Mr. Joseph Defeo
    Global Head of Managed Services Production














ENFN Stock Analysis - Frequently Asked Questions

Should I buy or sell Enfusion stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ENFN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENFN, but not buy additional shares or sell existing shares.
View ENFN analyst ratings
or view top-rated stocks.

What is Enfusion's stock price target for 2024?

6 brokers have issued 12 month price objectives for Enfusion's shares. Their ENFN share price targets range from $9.00 to $12.00. On average, they expect the company's share price to reach $10.17 in the next twelve months. This suggests a possible upside of 4.3% from the stock's current price.
View analysts price targets for ENFN
or view top-rated stocks among Wall Street analysts.

How have ENFN shares performed in 2023?

Enfusion's stock was trading at $9.67 at the beginning of 2023. Since then, ENFN stock has increased by 0.8% and is now trading at $9.75.
View the best growth stocks for 2023 here
.

Are investors shorting Enfusion?

Enfusion saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 1,910,000 shares, a drop of 12.8% from the October 31st total of 2,190,000 shares. Based on an average trading volume of 318,800 shares, the short-interest ratio is presently 6.0 days. Currently, 4.2% of the company's stock are short sold.
View Enfusion's Short Interest
.

When is Enfusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our ENFN earnings forecast
.

How were Enfusion's earnings last quarter?

Enfusion, Inc. (NYSE:ENFN) posted its quarterly earnings results on Tuesday, November, 7th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.01. The company earned $44.36 million during the quarter, compared to analyst estimates of $43.95 million. Enfusion had a trailing twelve-month return on equity of 9.13% and a net margin of 3.67%.

When did Enfusion IPO?

(ENFN) raised $300 million in an initial public offering on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share.

Who are Enfusion's major shareholders?

Enfusion's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include New York State Common Retirement Fund (1.31%), Hudson Bay Capital Management LP (0.36%), Northern Trust Corp (0.27%), Charles Schwab Investment Management Inc. (0.23%), Bank of New York Mellon Corp (0.10%) and AQR Capital Management LLC (0.07%). Insiders that own company stock include Bronwen Bastone, Dan Groman, Hillhouse Investment Managemen, Oleg Movchan, Roy Luo, Stephen Malherbe and Tarek Hammoud.
View institutional ownership trends
.

How do I buy shares of Enfusion?

Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:ENFN) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -